ibex (IBEX) Q2 2026 earnings review
Outrunning the Sector: Growth Accelerates, Guidance Raised
IBEX continues to defy the broader BPO slowdown, delivering its fourth consecutive quarter of double-digit growth. Revenue rose 17% YoY to a record $164.2M, driven by a massive 35% surge in HealthTech. Profitability improved alongside volume, with Adjusted EBITDA margins expanding 80bps to 12.6%. While the aggressive growth required a near-tripling of CapEx (pushing Free Cash Flow negative), management signaled high confidence by raising full-year revenue and EBITDA guidance.
🐂 Bull Case
While legacy BPO players struggle with single-digit growth or contraction, IBEX is accelerating (17% YoY). The company is successfully winning market share ('trophy clients') from larger competitors.
The HealthTech vertical grew 35.1% YoY, proving IBEX can win in complex, high-value regulated industries rather than just commoditized customer support.
🐻 Bear Case
Free Cash Flow turned negative (-$5.1M) as CapEx surged to $11.7M (up 170% YoY). The company is spending heavily to build capacity; if demand softens, this fixed cost expansion becomes a liability.
Despite the guidance raise, the midpoint ($625M) implies H2 revenue of ~$310M, which is effectively flat to down vs H1 ($315M). Growth rates will face much tougher comps in Q3/Q4.
⚖️ Verdict: 🟢🟢
Bullish. IBEX is executing a 'land and expand' strategy perfectly. The margin expansion (despite heavy reinvestment) and consistent double-digit organic growth justify the aggressive CapEx spend. The raise in guidance confirms the momentum is real.
Key Themes
HealthTech Leading Vertical Expansion
Accelerating. HealthTech has become the primary growth engine, surging 35.1% YoY. This outpaces Retail & E-commerce (+17.2%) and Travel (+20.2%). Winning in this vertical is critical as it typically carries higher barriers to entry and stickier client relationships than general retail support.
Capital Intensity Spike
Reversing. Free Cash Flow fell to negative $5.1M, a deterioration from negative $3.2M a year ago. The driver is a sharp spike in CapEx to $11.7M (vs $4.3M in 25Q2) to support capacity expansion in high-margin regions. While this indicates demand, it temporarily drains liquidity and breaks the trend of FCF generation seen in FY25.
Margin Expansion via Offshore Mix
Stable/Improving. Adjusted EBITDA margin expanded 80 bps YoY to 12.6%. Management explicitly attributes this to faster growth in higher-margin offshore regions and lower SG&A as a percentage of revenue. This demonstrates operating leverage is kicking in despite the aggressive top-line expansion.
AI as a Competitive Moat
Management continues to position AI not as a threat to billable hours, but as a differentiator ('AI Agents') enabling them to win market share. They claim the strong results are a direct consequence of deploying AI solutions for clients, though specific revenue breakout for AI-only services remains undisclosed.
Other KPIs
Accelerating. Up 46% YoY ($0.59 in 25Q2). Growth was aided by a reduced share count (repurcahses) and higher Net Income margins (7.8% vs 6.8%).
Stable. Ideally would be higher given profitability, but heavily impacted by share repurchases ($2.9M in quarter) and the CapEx surge. Liquidity remains sufficient but is not accumulating as fast as earnings.
Accelerating. Up 25.2% YoY, outpacing revenue growth of 16.7%. This indicates high quality growth rather than 'buying revenue' at lower margins.
Guidance
Raised (previously $605-$620M). Implies ~12% YoY growth at midpoint. However, H1 actual revenue was $315.4M. The implied H2 revenue is $304.6M - $314.6M, which signals a sequential deceleration (Stable to Decelerating) vs H1 run-rate.
Raised (previously $78-$81M). Midpoint ($81M) implies a ~13% margin for the full year. Given H1 EBITDA was $40.2M, the guidance implies H2 EBITDA will be roughly equal to H1 ($40.8M), maintaining margins despite the implied revenue flattening.
Accelerating. Management explicitly stated they expect to be at the 'upper end' of the range. With $19.4M spent in H1, this implies a significant drop-off in CapEx for H2 (~$5.6M remaining at upper bound), which should help Free Cash Flow recover in Q3/Q4.
Key Questions
CapEx Cadence and FCF Recovery
You spent ~$19.4M on CapEx in H1 against a full-year guide of $25M (max). Does this imply CapEx falls off a cliff in H2, guaranteeing strong FCF generation, or is there a risk the CapEx guide moves higher?
H2 Revenue Conservatism
Implied H2 revenue guidance is flat-to-down versus H1 ($315M). Given the momentum in HealthTech and new logo wins, is this conservatism or are you seeing delayed decision-making in the pipeline?
AI Revenue Cannibalization
As AI Agents gain traction, have you seen any deflationary pressure on seat-count revenue in your legacy Retail/E-commerce cohorts, or is the volume growth purely additive?